Skip to main content
Banner

Course Details

Released On

January 14, 2026

Expires On

January 13, 2027

Media Type

Internet

Specialties

Cardiology, Endocrinology, Hepatology, Pharmacy

Completion Time

60 minutes

Topics

Liver, Obesity

Providers/Grant Support

This activity is provided by MLI, in collaboration with WCIRDC and MEEF.

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credits Available

  • Physicians — maximum of 1.00 AMA PRA Category 1 Credits
  • Physician ABIM MOC — up to 1.00 MOC points
  • Physician Associates — up to 1.00 AAPA Category 1 CME credits
  • Nurses  — 1.0 contact hour
  • Pharmacists — 1.00 contact hour (0.1 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

Endocrinologists, general and internal medicine specialists, hepatologists, advanced practice providers (APPs), pharmacists, and cardiologists who provide care to patients with obesity and associated comorbidities, including MASLD and MASH, CVD, T2D, and CKD.

Program Overview

This independent satellite symposium, held during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), will address the urgent need for clinician education on obesity and its complex, multifactorial relationship with metabolic diseases. Faculty experts will explore the pathophysiological links between obesity and metabolic dysfunction–associated steatotic liver disease (MASLD) and steatohepatitis (MASH), highlight evidence-based strategies for screening and diagnosis, and review emerging therapeutic options.

Designed for endocrinologists, internists, hepatologists, advanced practice providers, pharmacists, and cardiologists, this activity will equip learners with the knowledge to optimize early detection and integrated management of obesity and obesity-related comorbidities, improving outcomes across diverse patient populations.

Learning Objectives

After completing this activity, the learner should be better able to:

  • Outline the pathophysiological processes leading to the development of obesity and associated comorbidities including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunctionassociated steatohepatitis (MASH)
  • Implement evidence-based best practices for screening for and diagnosis of MASLD and MASH in patients with obesity
  • Evaluate new treatment approaches for obesity and MASLD/MASH

Faculty

Dinani 135

Amreen M. Dinani MD, FRCPC

Associate Professor of Medicine 
Duke University School of Medicine
Durham, NC, USA

Green J 135

Jennifer B. Green MD

Professor of Medicine 
Duke University School of Medicine
Durham, NC, USA

Kushner R 135

Robert F. Kushner MD

Professor Emeritus 
Northwestern Medicine
Chicago, IL, USA

Accreditation, Support and Credit

In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education

Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit

PA

Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until January 13, 2027.  PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour.

Pharmacy

Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. 

Universal Activity Number: JA0007322-0000-26-005-H01-P

For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure & Conflict of Interest Policy

Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity. 

Faculty Disclosures

Chair/Planner/Presenter
Robert F. Kushner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Antag, AstraZeneca, Boehringer Ingelheim, Currax, Eli Lilly, Novo Nordisk, Regeneron, Structure, Weight Watchers

Planner/Presenter
Amreen Dinani, MD, FRCPC, ABOM, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Madrigal, Novo Nordisk, Petauri Kinetix
Other: Principal Investigator for site for industry studies: Akero, 89bio, Hanmi, Inventiva, Madrigal

Planner/Presenter
Jennifer Green, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Anji, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Lilly, Merck, Mineralys, Novo Nordisk, Sanofi, Valo, Vertex
Research Funding: Bluedrop (ended), Boehringer Ingelheim, Lilly, Merck, Roche

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.  You will receive your certificate from Medical Learning Institute Inc

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

About This Activity

Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters. 

Copyright © 2026 Medical Learning Institute Inc.  All Rights Reserved.

Contact Information

If you have questions regarding your certificate, please contact MLI at [email protected].